Ann: Appendix 3B - Star Bright Placement Issue, page-9

It would be nice to restart trading after:

1) Enough cost cuttings to put the spiralling costs under control.

2) Have a sure realistic plan to profitability.

3) Maybe a second cornerstone investor.

4) our cornerstone investors somehow helping with the cost of tavr development for a bigger slice for them in Tavr.

5) Sell infusion division which will bring us down below the 20 million threshold to receive refunds from R&D expenses.

6) meaningful salary cuts until we hit cash positive, maybe give shares instead of cash.

7) directors buying on market to support the share price and help return confidence in the stock to show worst is behind us.

Another big issue is trust, they will have to work very hard to earn back the trust they lost, uphill battle for this one, but simple by following this rule:

Trust starts with truth and ends with truth

I remain hopeful after all this pain, there is light at the end of the tunnel.